FIVE PRIME THERAPEUTICS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $8.4M | $5.3M | $49.9M | $39.5M | $30.7M | $4.3M |
| Operating income | −$92.9M | −$141.9M | −$146.2M | −$151.4M | −$99.2M | $287.0M |
| Net income | −$20.1M | −$35.4M | −$140.4M | −$150.2M | −$65.7M | $249.6M |
| Total assets | $331.6M | $224.1M | $321.5M | $344.0M | $448.3M | $548.3M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $265.1M | $150.5M | $265.1M | $265.2M | $391.6M | $433.2M |
| EPS (diluted) | — | — | — | $-5.38 | $-2.44 | $9.23 |
| Shares out. | 36.4M | 35.5M | 34.9M | 29.0M | 27.8M | 25.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −1103.8%
- Net margin
- −239.1%
- Return on equity
- −7.6%
- Return on assets
- −6.1%
- Return on capital (ROCE)
- −30.0%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $7.28
- Revenue growth (YoY)
- 57.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Accruals / assets
- 13.4%high accruals
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 16, 2021
- Other material eventApr 15, 2021
- Entered a material agreement · Other material eventMar 4, 2021
- Results of operationsJan 15, 2021
- Other material eventJan 15, 2021
- Other material eventNov 17, 2020
- Entered a material agreement · Other material eventNov 13, 2020
- Other material eventNov 10, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 15, 2022
- SC 13G/AMay 17, 2021
- 15-12BApr 26, 2021
- EFFECTApr 21, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
- 4FORM 4 SUBMISSIONApr 19, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.